G
Gunnar B. Kristensen
Researcher at Oslo University Hospital
Publications - 240
Citations - 16506
Gunnar B. Kristensen is an academic researcher from Oslo University Hospital. The author has contributed to research in topics: Ovarian cancer & Cancer. The author has an hindex of 62, co-authored 232 publications receiving 14625 citations. Previous affiliations of Gunnar B. Kristensen include University of Oslo & Rikshospitalet–Radiumhospitalet.
Papers
More filters
Journal ArticleDOI
A phase 3 trial of bevacizumab in ovarian cancer.
Timothy J. Perren,Ann Marie Swart,Jacobus Pfisterer,Jonathan A. Ledermann,Eric Pujade-Lauraine,Gunnar B. Kristensen,Mark S. Carey,Philip Beale,Andrés Cervantes,Christian Kurzeder,Andreas du Bois,Jalid Sehouli,Rainer Kimmig,A. Stähle,Fiona Collinson,Sharadah Essapen,Charlie Gourley,Alain Lortholary,Frédéric Selle,Mansoor Raza Mirza,Arto Leminen,Marie Plante,Dan Stark,Wendi Qian,Wendi Qian,Mahesh K. B. Parmar,Amit M. Oza,Icon investigators +27 more
TL;DR: In patients at high risk for progression, the benefit was greater with bevacizumab than without it, with progression-free survival (restricted mean) at 42 months of 14.5 months, higher than the average for women with ovarian cancer.
Journal ArticleDOI
Bevacizumab Combined With Chemotherapy for Platinum-Resistant Recurrent Ovarian Cancer: The AURELIA Open-Label Randomized Phase III Trial
Eric Pujade-Lauraine,Felix Hilpert,Béatrice Weber,Alexander Reuss,Andreas Poveda,Gunnar B. Kristensen,Roberto Sorio,Ignace Vergote,Petronella O. Witteveen,Aristotelis Bamias,Deolinda Pereira,Pauline Wimberger,Ana Oaknin,Mansoor Raza Mirza,Philippe Follana,David T. Bollag,Isabelle Ray-Coquard +16 more
TL;DR: Adding bevacizumab to chemotherapy statistically significantly improved PFS and ORR; the OS trend was not significant.
Journal ArticleDOI
Gene Expression Programs in Response to Hypoxia: Cell Type Specificity and Prognostic Significance in Human Cancers
Jen-Tsan Chi,Jen-Tsan Chi,Zhen Wang,Dimitry S.A. Nuyten,Edwin H. Rodriguez,Marci E. Schaner,Ali Salim,Yun Wang,Gunnar B. Kristensen,Åslaug Helland,Anne Lise Børresen-Dale,Amato J. Giaccia,Michael T. Longaker,Trevor Hastie,George P. Yang,Marc J. van de Vijver,Patrick O. Brown +16 more
TL;DR: A gene-expression signature of the hypoxia response, derived from studies of cultured mammary and renal tubular epithelial cells, showed coordinated variation in several human cancers, and was a strong predictor of clinical outcomes in breast and ovarian cancers.
Journal ArticleDOI
Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial.
Amit M. Oza,Adrian Cook,Jacobus Pfisterer,Andrew C. Embleton,Jonathan A. Ledermann,Eric Pujade-Lauraine,Gunnar B. Kristensen,Mark S. Carey,Philip Beale,Andrés Cervantes,Tjoung Won Park-Simon,Gordon J. S. Rustin,Florence Joly,Mansoor Raza Mirza,Marie Plante,Michael A. Quinn,Andres Poveda,Gordon C Jayson,Dan Stark,Ann Marie Swart,Laura Farrelly,Richard Kaplan,Mahesh K. B. Parmar,Timothy J. Perren +23 more
TL;DR: The ICON7 trial previously reported improved progression-free survival in women with ovarian cancer with the addition of bevacizumab to standard chemotherapy, with the greatest effect in patients at high risk of disease progression, so evidence of non-proportional hazards was shown.
Journal ArticleDOI
Pegylated Liposomal Doxorubicin and Carboplatin Compared With Paclitaxel and Carboplatin for Patients With Platinum-Sensitive Ovarian Cancer in Late Relapse
Eric Pujade-Lauraine,Uwe Wagner,Elisabeth Aavall-Lundqvist,Val Gebski,Mark Heywood,Paul Vasey,Birgit Volgger,Ignace Vergote,Sandro Pignata,Annamaria Ferrero,Jalid Sehouli,Alain Lortholary,Gunnar B. Kristensen,Christian Jackisch,Florence Joly,Chris Brown,Nathalie Le Fur,Andreas du Bois +17 more
TL;DR: This trial is the largest in recurrent ovarian cancer and has demonstrated superiority in PFS and better therapeutic index of CD over standard CP and better quality of life, and overall survival.